GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (LSE:RENX) » Definitions » Intrinsic Value: Projected FCF

Renalytix (LSE:RENX) Intrinsic Value: Projected FCF : £0.00 (As of May. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Renalytix Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-24), Renalytix's Intrinsic Value: Projected FCF is £0.00. The stock price of Renalytix is £0.195. Therefore, Renalytix's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Renalytix's Intrinsic Value: Projected FCF or its related term are showing as below:

LSE:RENX's Price-to-Projected-FCF is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.285
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Renalytix Intrinsic Value: Projected FCF Historical Data

The historical data trend for Renalytix's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Intrinsic Value: Projected FCF Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Renalytix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Renalytix's Intrinsic Value: Projected FCF

For the Health Information Services subindustry, Renalytix's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renalytix's Price-to-Projected-FCF Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Renalytix's Price-to-Projected-FCF falls into.



Renalytix Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Renalytix  (LSE:RENX) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Renalytix's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.195/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renalytix Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Renalytix's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix (LSE:RENX) Business Description

Traded in Other Exchanges
Address
5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix (LSE:RENX) Headlines

From GuruFocus

Paul Singer Buys Reed Elesvier

By matsandalex matsandalex 12-14-2012

Investing in Information

By Vanina Egea Vanina Egea 03-06-2014

Causeway International's Top Five Holdings

By Monica Wolfe Monica Wolfe 08-29-2013